You are here



The Board of Directors of NorDiag has today approved the Company's annual financial statement for 2010. There are no material changes compared to the preliminary results, which were published on 18 February 2011.

The Company's complete Annual Report for 2010 (English) is attached to this stock exchange notice. NorDiag has obtained necessary exemptions for only reporting the annual financial statement in English.

The Annual Report 2010 is also available at the Company's website;

CFO Tone Kvåle, phone +47 915 19576
About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and reagents) for sample preparation of DNA from difficult biological samples. DNA diagnostics give more rapid and precise answers, and are the fastest growing field within diagnostics. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The Company has offices and laboratories in Stockholm, Sweden, in West Chester (PA), USA and in Vienna, Austria. The group has today 41.1 man-labour years. NorDiag is listed on Oslo Stock Exchange with ticker NORD.

For further information -
This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)